LitCovid-sentences  

PMC:7242013 / 2493-8116 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T32 0-114 Sentence denotes Table 1 Selected AASLD, APASL, and EASL Recommendations for Liver Disease Management During the COVID‐19 Pandemic
T33 115-150 Sentence denotes Recommendations AASLD APASL EASL
T34 151-225 Sentence denotes Limit nosocomial transmission Prioritize patients to limit in‐person care
T35 226-372 Sentence denotes On arrival, screen patients for COVID‐19 symptoms, exposures; if suggestive of COVID‐19, refer care per clinic’s protocol for symptomatic patients
T36 373-419 Sentence denotes Use telemedicine alternatives for routine care
T37 420-468 Sentence denotes Reduce routine laboratory and imaging monitoring
T38 469-501 Sentence denotes Prescribe 90 days of medications
T39 502-566 Sentence denotes Cancel all elective/nonurgent endoscopic procedures and biopsies
T40 567-609 Sentence denotes Limit in‐clinic evaluations for transplant
T41 610-668 Sentence denotes Limit clinical trial activity to essential clinical trials
T42 669-715 Sentence denotes Limit HCWs providing care or on patient rounds
T43 716-799 Sentence denotes HCWs follow recommendations for PPE Use telemedicine alternatives for routine care
T44 800-843 Sentence denotes Minimize number of HCWs caring for patients
T45 844-885 Sentence denotes Minimize number of HCWs on patient rounds
T46 886-943 Sentence denotes Cancel elective, nonurgent endoscopies and liver biopsies
T47 944-1017 Sentence denotes HCWs follow recommendations for PPE Limit in‐person care to urgent cases
T48 1018-1060 Sentence denotes Remodel clinic space for social distancing
T49 1061-1122 Sentence denotes Use telemedicine for routine care; postpone specialist visits
T50 1123-1183 Sentence denotes Reduce frequency of laboratory monitoring and obtain locally
T51 1184-1219 Sentence denotes HCWs follow recommendations for PPE
T52 1220-1485 Sentence denotes Evaluate and care for patients with COVID‐19 for liver disease Prioritize for COVID‐19 testing: (1) patients with cirrhosis, (2) patients with CLD receiving immunosuppressive medications, and (3) patients with new‐onset encephalopathy or other acute decompensation
T53 1486-1524 Sentence denotes Regularly monitor liver biochemistries
T54 1525-1647 Sentence denotes Consider non‐COVID‐19 etiologies for liver disease: (1) exacerbation of preexisting CLD or (2) drug‐induced hepatotoxicity
T55 1648-1697 Sentence denotes Use acetaminophen 2 g/day as preferred medication
T56 1698-1748 Sentence denotes Use nonsteroidal anti‐inflammatory drugs as needed
T57 1749-1876 Sentence denotes Consult the University of Liverpool document to assess possible drug interactions Follow WHO guidelines for COVID‐19 diagnosis
T58 1877-1934 Sentence denotes Consider NAFLD as a prognostic factor for severe COVID‐19
T59 1935-1982 Sentence denotes Screen patients for hepatitis B surface antigen
T60 1983-2066 Sentence denotes Consider HBV prophylaxis prior to use of anti‐IL‐6, other immunosuppressive therapy
T61 2067-2116 Sentence denotes Monitor liver function tests of patients with CLD
T62 2117-2157 Sentence denotes Be alert to possible drug hepatotoxicity
T63 2158-2237 Sentence denotes Decompensated CLD and ALT >5 times ULD contraindications for remdesivir therapy
T64 2238-2397 Sentence denotes Prioritize persons with CLD for clinical trials Test for COVID‐19 patients with acute decompensation or acute‐on‐chronic liver and per institution’s practices
T65 2398-2476 Sentence denotes Persons with NAFLD likely to have comorbidity risk factors for severe COVID‐19
T66 2477-2551 Sentence denotes Consider patients with CLD/COVID‐19 for early admission and clinical trial
T67 2552-2599 Sentence denotes Use acetaminophen (2–3 g/day is generally safe)
T68 2600-2649 Sentence denotes Limit use of nonsteroidal anti‐inflammatory drugs
T69 2650-2760 Sentence denotes Test for COVID‐19 patients with acute decompensation or acute‐on‐chronic liver and per institution’s practices
T70 2761-2839 Sentence denotes Persons with NAFLD likely to have comorbidity risk factors for severe COVID‐19
T71 2840-2914 Sentence denotes Consider patients with CLD/COVID‐19 for early admission and clinical trial
T72 2915-2962 Sentence denotes Use acetaminophen (2–3 g/day is generally safe)
T73 2963-3012 Sentence denotes Limit use of nonsteroidal anti‐inflammatory drugs
T74 3013-3102 Sentence denotes Manage hepatitis B; hepatitis C Continue HBV and HCV treatment of patients with COVID‐19
T75 3103-3190 Sentence denotes Proceed with HBV and HCV treatment in patients without COVID‐19 as clinically warranted
T76 3191-3330 Sentence denotes Do not consider HBV treatment in patients with COVID‐19 unless flare is suspected Continue HBV and HCV treatment of patients with COVID‐19
T77 3331-3418 Sentence denotes Proceed with HBV and HCV treatment in patients without COVID‐19 as clinically warranted
T78 3419-3500 Sentence denotes Do not consider HBV treatment in patients with COVID‐19 unless flare is suspected
T79 3501-3572 Sentence denotes Document discussion with patient regarding CLD diagnosis and management
T80 3573-3685 Sentence denotes Manage patients with HCC Continue HCC surveillance schedule for high‐risk subjects; 2‐month delay is acceptable
T81 3686-3765 Sentence denotes Document discussion of risks and benefits of delaying surveillance with patient
T82 3766-3852 Sentence denotes Proceed with HCC treatments as appropriate Continue therapy for non‐COVID‐19 patients
T83 3853-3994 Sentence denotes For patients with HCC with COVID‐19, postpone elective transplant and resection surgery, withhold immunotherapy Maintain care per guidelines
T84 3995-4031 Sentence denotes Admit early if COVID‐19 is diagnosed
T85 4032-4065 Sentence denotes Consider postponing HCC therapies
T86 4066-4156 Sentence denotes Manage pretransplant and posttransplant patients Screen donors and recipient for COVID‐19
T87 4157-4228 Sentence denotes Do not postpone transplants (an essential medical service, CMS Tier 3b)
T88 4229-4298 Sentence denotes Notify patients of possible extended waiting times on transplant list
T89 4299-4391 Sentence denotes Have low threshold for admitting patients on transplant waiting list diagnosed with COVID‐19
T90 4392-4506 Sentence denotes For posttransplant patients with moderate COVID‐19, consider reduction of immunosuppression therapy as appropriate
T91 4507-4625 Sentence denotes Do not reduce immunosuppressive therapy in patients with mild COVID‐19 disease Test donors and recipient for COVID‐19
T92 4626-4680 Sentence denotes Limit transplant listing to emergency and urgent cases
T93 4681-4768 Sentence denotes Look for SARS‐COV‐2 prior to organ procurement; defer donors with evidence of infection
T94 4769-4842 Sentence denotes Consider specific COVD‐19 consent for patients on transplant waiting list
T95 4843-4956 Sentence denotes For posttransplant patient with moderate COVID‐19, consider reduction of immunosuppression therapy as appropriate
T96 4957-5065 Sentence denotes Do not reduce immunosuppressive therapy in patients with mild COVID‐19 disease Maintain care per guidelines
T97 5066-5139 Sentence denotes Limit transplantation listings to patients with poor short‐term prognosis
T98 5140-5175 Sentence denotes Vaccinate against pneumonia and flu
T99 5176-5221 Sentence denotes Avoid reductions in immunosuppressive therapy
T100 5222-5292 Sentence denotes Do not reduce immunosuppressive therapy in patients with mild COVID‐19
T101 5293-5440 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T102 5441-5623 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.